T. Rowe Price Reports 10.1% Stake in Bicara Therapeutics Inc (BCAX)

T. Rowe Price Investment Management, Inc. filed a Schedule 13G/A on April 8, 2026, reporting a significant increase in its position in Bicara Therapeutics Inc (BCAX). As of the event date on March 31, 2026, the investment adviser beneficially owns 6,605,780 shares of Common Stock, representing a 10.1% ownership stake in the company. This filing marks an amendment to a previous position, which was recorded at 0.0% in prior snapshots, indicating a major new accumulation of shares. The filing specifies that T. Rowe Price has sole dispositive power over all 6,605,780 shares and sole voting power over 6,597,481 shares. The securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This substantial holding positions T. Rowe Price as a major institutional investor in the Cambridge-based biotechnology firm.